EUCTR2016-002831-14-DK进行中（未招募）1 期
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies (FIGHT-101)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 325
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female subjects, age 18 years or older on day of signing consent.
- •2. Willingness to provide written informed consent for the study.
- •3. Part 1: Any advanced solid tumor malignancy.
- •Part 2: Subjects with measurable disease with documented FGF/FGFR alterations, including multiple myeloma and MPNs . For subjects enrolling in Part 2 with lead head and neck, vulvar, or anal cancer, must have evidence of positive HPV status. For BID dosing in Part 2, subjects must have a documented FGFR3 mutation or fusion-positive with advanced/metastatic bladder cancer.
- •1) Dose finding: subjects with solid tumor malignancies that have measurable disease for which treatment with gemcitabine + cisplatin, docetaxel, pembrolizumab, or trastuzumab is relevant.
- •2) Dose expansion: subjects with solid tumor malignancies that have measurable disease and are also harboring FGF/FGFR alterations for which treatment with gemcitabine + cisplatin, docetaxel, pembrolizumab, or trastuzumab is relevant.
- •4. Has progressed after prior therapy and either there is no further effective standard anticancer therapy available (including subject refuses or is intolerant) or the prescribed combination therapy for subjects enrolling in Part 3 is considered a relevant therapy for their diagnosis.
- •5. Life expectancy > 12 weeks.
- •6. ECOG performance status:
- •Part 1: 0 or 1.
- •Parts 2 and 3: 0, 1, or 2.
- •7. Archival tumor specimen (tumor block or 25 unstained slides, minimum number of slides is approximately15) or willingness to undergo a pretreatment tumor biopsy to provide a tumor block or 25 unstained slides (minimum number of slides is approximately 15). Archival tumor biopsies are acceptable at baseline and should be no more than 2 years old (preferably less than 1 year old and collected since the completion of the last treatment); subjects with samples older than 2 years old and/or with sequencing report from Foundation Medicine require approval from the sponsor medical monitor for exemption from the need for tumor biopsy or tumor sample requirement.
- •NOTE: For subjects in Part 1, fresh tumor biopsies for the purpose of determining study eligibility should be limited to tumors where tissue can be safely accessed. The medical monitor should be contacted before the subject is enrolled.
- •8. Women of childbearing potential (defined as women who have not undergone surgical sterilization with a hysterectomy and/or bilateral oophorectomy and are not postmenopausal or sterilized from chemo/radiotherapy, defined as = 12 months of amenorrhea) must have a negative serum pregnancy test at screening and prior to the first dose on Cycle 1 Day 1. All women and men of childbearing potential must agree to take appropriate precautions to avoid pregnancy or fathering children (with at least 99%certainty) from screening through the safety follow-up visit (30-35 days after last dose). Subjects enrolled in Part 3 combination with INCMGA00012 should avoid pregnancy or fathering a child starting at screening through 6 months after the last dose of INCMGA00012. Permitted methods that are at least 99% effective in preventing pregnancy (Appendix A) should be communicated to the subject and their understanding confirmed.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 221
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 104
排除标准
- •Treatment with other investigational study drug for any indication for any reason, or receipt of anticancer medications within 28 days before first dose of study drug (6 wks for mitomycin-C or nitrosoureas, 7 days for tyrosine kinase inhibitors), but may be eligible with approval from the sponsor's medical monitor (MM).
- •- Subjects must have recovered (= Grade 1 or pretherapy baseline) from AEs due to previously administered therapies.
- •Prior receipt of a selective FGFR inhibitor within the last 6 months
- •Laboratory parameters outside Protocol-defined range.
- •Part 1 Dose Escalation:
- •- Hemoglobin < 10.0 g/dL (transfusions are permitted with approximately 2 weeks of washout required before enrolment (TFP)).
- •- Platelet count < 100 × 109/L
- •- Absolute neutrophil count < 1.5 × 109/L
- •- Total bilirubin > upper limit of normal (ULN) unless associated with subject's primary cancer and/or metastases and with MM approval (**Unless Associated)
- •- AST or ALT > ULN **Unless Associated
- •- ALP > ULN **Unless Associated
- •- Creatinine clearance = 60 mL/min (< 30 mL/min for urothelial carcinoma) based on the site's standard formula
- •- Serum calcium outside of the institutional normal range (INR), or serum albumin-corrected calcium outside of INR if serum albumin is outside of INR
- •- Serum phosphorus outside of the ULN of INR
- •- Parathyroid hormone > 1.5 x ULN of INR
- •Part 2 Expansion:
- •- Hemoglobin = 9.0 g/dL (TFP)
- •- Platelet count = 75 × 109/L
- •- Absolute neutrophil count = 1.0 × 109/L
- •- Total bilirubin = 1.5 × institutional ULN **Unless Associated
- •- AST or ALT = 3 × ULN **Unless Associated
- •- ALP = 2.5 × ULN **Unless Associated
- •- Creatinine clearance = 40 mL/minute (< 30 mL/min for multiple myeloma or urothelial carcinoma) based on the site's standard formula
- •- Serum calcium outside of INR, or serum albumin-corrected calcium outside of INR if serum albumin is outside of INR
- •- Serum phosphorus outside of the ULN of INR
- •- Parathyroid hormone > 1.5 x ULN of INR
- •Note: Hematological parameters do not apply to subjects with MPN.
- •Part 3 Combination:
- •- Hemoglobin = 9.0 g/dL (TFP)
- •- Platelet count = 75 × 109/L
- •- Absolute neutrophil count = 1.5 × 109/L
- •- Total bilirubin = 1.5 × institutional ULN **Unless Associated
- •- AST or ALT = 3 × ULN **Unless Associated
- •- ALP = 2.5 × ULN **Unless Associated
- •- Creatinine clearance = 40 mL/minute (< 30 mL/min for urothelial carcinoma) based on the site's standard formula
- •- International normalized ratio or prothrombin time > 1.5 × ULN, unless on warfarin
- •- Activated partial thromboplastin time > 1.5 × ULN
- •- Serum calcium outside of INR, or serum albumin-corrected calcium outside of INR when serum albumin is outside of INR
- •- Serum phosphorus outside of the ULN of INR
- •- Parathyroid hormone > 1.5 x ULN of INR
- •History of a calcium/phosphate homeostasis disorder.
- •History of hypersensitivity to any of the study drugs.
- •History and/or current evidence of ectopic mineralization/calcification, except intratumoral calcification secondary to tumor necrosis or previous treatment (eg, transarterial chemoembolization, chemotherapy) and calcified lymph nodes and asymptomatic arterial or cartilage/tendon calcification.
- •Current evidence of corneal disorder/keratopathy, including but not limited to bullous/band keratopathy, corneal abrasion, inflammation/ulceration, keratoconjuctivitis, etc, confirmed by ophthalmologic examination.
- •History or presence of an abnormal ECG that in the investigator's opinion
研究者
相似试验
进行中（未招募）
1 期
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid TumorsEUCTR2016-002079-93-GBIncyte Biosciences International Sàrl163
进行中（未招募）
1 期
A Phase 1/2, Open-Label, Dose-Rising , Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or MetastaticCancers (ECHO-208)EUCTR2017-001743-12-GBIncyte Corporation141
招募中
1 期
A Study of Oral TP-3654 in Patients With MyelofibrosisMyelofibrosisJPRN-jRCT2031210490Koike Haruhiko60
进行中（未招募）
1 期
Safety and Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia AEUCTR2019-004210-33-GBSigilon Therapeutics, Inc.18
进行中（未招募）
1 期
A Phase 1/2a, Open Label, Dose Escalation, Safety Study of Intra-thrombus Plasmin (Human) Administration in Acute, Middle Cerebral Artery, Ischemic Strokethrombus in acute ischemic stroke of the middle cerebral arteryMedDRA version: 12.0Level: HLTClassification code 10007948Term: Central nervous system haemorrhages and cerebrovascular accidentsEUCTR2009-012086-66-FRTalecris Biotherapeutics Inc40